The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study without human participants
PubMed 22563484 · doi:10.1371/journal.pone.0036197
What was done
Mice with intracranial bioluminescent malignant glioma implants were assigned to either a standard diet or a 4:1 ketogenic formula (KetoCal). Mice received 2 x 4 Gy whole-brain radiation, and tumor growth was monitored by in vivo imaging. Animals in the combined treatment group were returned to a standard diet at day 101 post-implantation to monitor for tumor recurrence.
What was found
Animals fed the ketogenic formula had significantly elevated beta-hydroxybutyrate levels (p = 0.0173) and an increased median survival of approximately 5 days compared to standard diet controls. Combining the ketogenic diet with radiation produced a greater-than-additive effect, reducing tumor bioluminescence below the detection threshold in 9 of 11 animals (p < 0.0001), with no recurrence observed for over 200 days following return to a standard diet.
Why it matters
This study provides preclinical proof-of-concept that dietary ketosis may act as a radiosensitizer in malignant glioma, offering a mechanistic rationale for testing ketogenic adjuvants in human neuro-oncology trials.
Limits
The study was conducted entirely in a rodent model, so clinical efficacy, adherence, and safety in human patients remain unknown. The total sample size across all treatment arms is not reported in the abstract.
Cited by
- supports Research by Dr. Adrienne Scheck showed that combining a dietary intervention with radiation enhanced cancer-specific immune regulation in a glioblastoma cell line.